Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 5K | 0 | 519K | 105K |
| Gross Profit | 0 | 2K | 0 | 250K | 0 |
| Operating Income | -8K | -19K | -418K | 224K | -13K |
| EBITDA | -8K | -19K | -418K | 224K | -13K |
| Net Income | -8K | -19K | -429K | 172K | -23K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$70.00
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rest Ez Inc. (RTEZ) is a Healthcare stock with a market cap of $1.93B and listed on OTC. The stock last traded around $70.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +70.1%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +70.1%, free cash flow +56.7% with operating margin 0.0% and ROIC 11.0%. Valuation already assumes a fairly strong business story at P/E 58411.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RTEZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RTEZ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RTEZ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RTEZ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$105.0K
-79.8% YoY
FY Net Income
-$23.2K
-113.5% YoY
Free Cash Flow
-$77.3K
-480.7% YoY
Revenue Growth
-100.0%
EPS Growth
+70.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 5K | 0 | 519K | 105K |
| Gross Profit | 0 | 2K | 0 | 250K | 0 |
| Operating Income | -8K | -19K | -418K | 224K | -13K |
| EBITDA | -8K | -19K | -418K | 224K | -13K |
| Net Income | -8K | -19K | -429K | 172K | -23K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 300 | 0 | 44 | 431 |
| Total Assets | 300 | 14K | 3K | 408K |
| Total Liabilities | 0 | 50K | 173K | 160K |
| Shareholder Equity | 300 | -37K | -171K | 248K |
| Total Debt | 0 | 8K | 131K | 118K |
| Net Debt | -300 | 8K | 131K | 118K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
77K
-480.7% YoY
Capital Expenditures
0
Free Cash Flow
77K
-480.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
11.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.